Piramal Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Piramal Pharma has a total shareholder equity of ₹79.1B and total debt of ₹47.9B, which brings its debt-to-equity ratio to 60.5%. Its total assets and total liabilities are ₹152.4B and ₹73.3B respectively. Piramal Pharma's EBIT is ₹6.5B making its interest coverage ratio 1.5. It has cash and short-term investments of ₹4.1B.
Key information
60.5%
Debt to equity ratio
₹47.86b
Debt
| Interest coverage ratio | 1.5x |
| Cash | ₹4.08b |
| Equity | ₹79.07b |
| Total liabilities | ₹73.35b |
| Total assets | ₹152.42b |
Recent financial health updates
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Recent updates
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Jan 31₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Financial Position Analysis
Short Term Liabilities: PPLPHARMA's short term assets (₹53.8B) exceed its short term liabilities (₹52.4B).
Long Term Liabilities: PPLPHARMA's short term assets (₹53.8B) exceed its long term liabilities (₹21.0B).
Debt to Equity History and Analysis
Debt Level: PPLPHARMA's net debt to equity ratio (55.4%) is considered high.
Reducing Debt: Insufficient data to determine if PPLPHARMA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PPLPHARMA's debt is not well covered by operating cash flow (14.2%).
Interest Coverage: PPLPHARMA's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 09:41 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Piramal Pharma Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |